NeuroThera expands U.S. patent portfolio with ibogaine

NeuroThera Labs files U.S. patents for ibogaine-based therapies

NeuroThera Labs Inc., a subsidiary of SciSparc Ltd., has announced the publication of three U.S. patent applications that cover innovative drug combinations involving ibogaine, according to a recent press release. These applications, developed in collaboration with Clearmind Medicine Inc., aim to address mental health disorders such as depression and PTSD, as well as substance use disorders.

Patent applications target mental health and substance use

The patent applications specifically focus on combinations of lysergic acid diethylamide (LSD), ketamine, and ibogaine with NeuroThera's proprietary technology, N-acylethanolamines, including palmitoylethanolamide (PEA). This initiative builds on previous intellectual property efforts, including a patent application for MDMA and N-acylethanolamines combinations. The goal is to develop new therapeutic approaches for various neuropsychiatric and substance use disorder indications.

Collaboration with Clearmind Medicine

NeuroThera's ongoing partnership with Clearmind Medicine is central to these developments. The collaboration is focused on creating safer and more effective treatments for prevalent mental health conditions by combining PEA with psychedelic-derived compounds. This strategy not only enhances NeuroThera's intellectual property portfolio but also supports the advancement of innovative therapeutic programs.

Why it matters

The expansion of NeuroThera's patent portfolio signifies a significant step forward in the development of novel treatments for mental health and substance use disorders. By leveraging the therapeutic potential of ibogaine and other psychedelic compounds, NeuroThera aims to address unmet needs in these rapidly growing areas. This could lead to more effective and safer treatment options for patients, potentially transforming the landscape of mental health care.

NeuroThera's efforts reflect a broader trend in the pharmaceutical industry towards exploring psychedelic compounds for therapeutic use.